Selected article for: "antiviral combination and influenza virus"

Author: Pizzorno, Andrés; Padey, Blandine; Terrier, Olivier; Rosa-Calatrava, Manuel
Title: Drug Repurposing Approaches for the Treatment of Influenza Viral Infection: Reviving Old Drugs to Fight Against a Long-Lived Enemy
  • Cord-id: mqvm4q22
  • Document date: 2019_3_19
  • ID: mqvm4q22
    Snippet: Influenza viruses still constitute a real public health problem today. To cope with the emergence of new circulating strains, but also the emergence of resistant strains to classic antivirals, it is necessary to develop new antiviral approaches. This review summarizes the state-of-the-art of current antiviral options against influenza infection, with a particular focus on the recent advances of anti-influenza drug repurposing strategies and their potential therapeutic, regulatory and economic be
    Document: Influenza viruses still constitute a real public health problem today. To cope with the emergence of new circulating strains, but also the emergence of resistant strains to classic antivirals, it is necessary to develop new antiviral approaches. This review summarizes the state-of-the-art of current antiviral options against influenza infection, with a particular focus on the recent advances of anti-influenza drug repurposing strategies and their potential therapeutic, regulatory and economic benefits. The review will illustrate the multiple ways to reposition molecules for the treatment of influenza, from adventitious discovery to in silico-based screening. These novel antiviral molecules, many of which targeting the host cell, in combination with conventional antiviral agents targeting the virus, will ideally enter the clinics and reinforce the therapeutic arsenal to combat influenza virus infections.

    Search related documents:
    Co phrase search for related documents
    • action mechanism target and acute sars cov respiratory syndrome coronavirus: 1, 2, 3
    • action pathology and acute sars cov respiratory syndrome coronavirus: 1
    • active site and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active site and low number: 1
    • actual evidence and acute sars cov respiratory syndrome coronavirus: 1
    • acute sars cov respiratory syndrome coronavirus and adamantane derivative: 1